
Windtree Therapeutics WINT
Quarterly report 2025-Q3
added 11-19-2025
Windtree Therapeutics DPO Ratio 2011-2026 | WINT
Annual DPO Ratio Windtree Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 145 | - | 983 | 265 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 983 | 145 | 464 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
405 | $ 0.88 | -2.07 % | $ 6.47 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.67 | 1.66 % | $ 3.76 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
CASI Pharmaceuticals
CASI
|
123 | - | - | $ 35.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
76.3 | - | -0.88 % | $ 598 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
Heron Therapeutics
HRTX
|
91.4 | $ 1.21 | 1.68 % | $ 202 M | ||
|
Aquestive Therapeutics
AQST
|
395 | $ 4.09 | -0.24 % | $ 437 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.29 | -0.56 % | $ 2.96 B | ||
|
ImmuCell Corporation
ICCC
|
19.5 | $ 8.35 | 1.21 % | $ 75.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.48 | 4.23 % | $ 394 M | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Kamada Ltd.
KMDA
|
106 | $ 8.15 | -0.61 % | $ 260 M | ||
|
bluebird bio
BLUE
|
182 | - | - | $ 546 M |